bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
August 10, 2021 07:00 ET | BioXcel Therapeutics
Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021
July 28, 2021 07:00 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
bioxcel-therapeutics-local-250x100.jpg
BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference
July 19, 2021 07:30 ET | BioXcel Therapeutics
NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ADVANCE-1 Pivotal Phase 2/3 Trial in Alzheimer’s Disease Agitation
April 27, 2020 06:00 ET | Axsome Therapeutics, Inc.
Statistically significant improvement in Alzheimer’s disease agitation, as measured by the CMAI total score compared to placebo (p=0.010, primary endpoint) Demonstrated rapid and substantial...
axsomelogo-468x57.jpg
Axsome Therapeutics Accelerates Completion of the ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
March 20, 2020 07:00 ET | Axsome Therapeutics, Inc.
Randomizations concluded and trial participation in process of concluding to ensure patient safety during COVID-19 pandemic AXS-05 and placebo arms fully enrolled with estimated completion rate of...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
December 10, 2018 07:00 ET | Axsome Therapeutics, Inc.
IDMC recommends continuation of trial evaluating AXS-05 versus placebo in Alzheimer’s disease agitation IDMC recommends no further enrollment to single-agent bupropion arm NEW YORK, Dec. 10, 2018 ...
axsomelogo-468x57.jpg
Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
September 19, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-05 Presentation at the 2018 Alzheimer’s Association International Conference
July 17, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, July 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces AXS-05 Poster Presentation at the 2018 Annual Meeting of the American Psychiatric Association
May 03, 2018 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, May 03, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...
axsomelogo-468x57.jpg
Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation
May 08, 2017 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, May 08, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system...